News

The research deal will target the development of new products that use the proprietary Ligand-developed LTP TECHNOLOGY to improve lipid-lowering activity of certain omega-3 fatty acids. Ligand president

Currently, Zestra is approved and marketed in Canada for the indication of ‘Temporary Increase of Desire in Female Sexual Desire Disorder Women (FSDD)’. The company said that the

Based on the company’s Localized Drug Action platform, AMA0076 is a highly potent locally-acting Rho Kinase (ROCK) inhibitor designed to reduce intraocular pressure (IOP) by acting specifically on

The products include COSOPT, COSOPT PF, TRUSOPT, TRUSOPT PF, TIMOPTIC, TIMOPTIC PF, TIMOPTIC XE, SAFLUTAN and TAPTIQOM. The company said that annual sales of these ophthalmology products in

EoE is a recently recognized allergic inflammatory disease, characterized by swelling of the esophagus and its symptoms include vomiting, abdominal pain, regurgitation and dysphagia. Due to the diverse

The approval is for doses 8mg, 12mg and 16mg of Exalgo (Hydromorphone Hydrochloride Extended-release Tablets). The drug is indicated for the management of moderate to severe pain in

The trial, to be conducted in China in accordance with international standards, will investigate the use of the Company’s developmental patient-specific cancer immunotherapy known as DC-TC, in patients

The exclusive license is inclusive of prescription and non-prescription rights for Bilastine, as well as adult and paediatric presentations in Canada. Terms of the agreement were not disclosed.

The new decision is expected to be published within six months. In Germany approximately 3,000 and 4,000 people with epilepsy have been treated with Fycompa since its launch